Resultados de la búsqueda 31-40 of 264 for fsa eligible items on amazon

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is ...

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with BRCA mutations are not excluded from this trial and are allowed to receive standard of care maintenance therapy including bevacizumab and/or PARP ...

3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Eligible patients will receive NACT with one cycle of carboplatin, followed by mirvetuximab + carboplatin (if FRα +) every 21 days for three cycles prior to ...

4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with BRCA mutations are not excluded from this trial and are allowed to receive standard of care maintenance therapy including bevacizumab and/or PARP ...

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is ...

6. Nutrición y comida saludable - Mayo Clinic

   Puedes hacerte experto en comida saludable aprendiendo cómo planear comidas y hacer compras de manera inteligente, y practicando técnicas para preparar ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with BRCA mutations are not excluded from this trial and are allowed to receive standard of care maintenance therapy including bevacizumab and/or PARP ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Durvalumab is FDA approved for treatment in lung cancers including non-small cell lung cancer and small cell lung cancer. Venetoclax is FDA approved for the ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...